€163.70
+2.20 (+1.36%)
EUR · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IPN.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
171 interventional · 116 observational · 102 with posted results
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During PregnancyNCT07556913observationalPrevalence of congenital malformations at birth | — | Recruiting | — | Pregnancy Related | 3 | 2039-01-31 | in 4,547 d | 2026-08-03 |
| A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)NCT06089616observationalPercentage of Participants With Treatment-emergent Adverse Events (TEAEs), whether or not they are considered as related to palovarotene | — | Recruiting | — | Fibrodysplasia Ossificans Progressiva | 100 | 2035-12-05 | in 3,394 d | 2026-07-02 |
| A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South KoreaNCT07185919observationalPercentage of participants experiencing Adverse Events (AEs) | — | Recruiting | — | Progressive Familial Intrahepatic Cholestasis | 10 | 2032-09-30 | in 2,233 d | 2026-08-03 |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing TreatmentNCT06447168observationalPercentage of participants with response to treatment | — | Recruiting | — | Primary Biliary Cholangitis | 424 | 2032-07-15 | in 2,156 d | 2026-08-03 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor TherapiesNCT07213830Percentage of participants with dose limiting toxicity (DLT)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: IPN01203 | Advanced Solid Tumor, Metastatic Solid Tumor | 102 | 2032-07-14 | in 2,155 d | 2026-07-30 |
| Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or LactationNCT06258902observationalPrevalence rate of major congenital malformations (MCM) at birth | — | Recruiting | — | Pregnancy Related | 20 | 2032-05-31 | in 2,111 d | 2026-08-03 |
| A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing TreatmentNCT07585097observationalPercentage of participants experiencing adverse events (AEs) | — | Recruiting | — | Alagille Syndrome | 30 | 2031-09-30 | in 1,867 d | 2026-08-03 |
| A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.NCT05627362Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Related TEAEs, Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)Randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg, Placebo Matched to Elafibranor 120 mg | Primary Sclerosing Cholangitis | 68 | 2031-09-23 | in 1,860 d | 2026-08-03 |
| A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive ChemotherapyNCT07623187(Phase 2b and Phase 3) Percentage of participants with Complete Remission (CR)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Not yet recruiting | Biological: IPN60340 + azacitidine + venetoclax · Drug: Placebo + azacitidine + venetoclax | Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia | 450 | 2031-05-31 | in 1,745 d | 2026-06-03 |
| A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisNCT07387549Event-Free SurvivalRandomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Elafibranor · Other: Placebo | Primary Sclerosing Cholangitis | 350 | 2031-04-30 | in 1,714 d | 2026-08-03 |
| A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in ChinaNCT07588880observationalPercentage of participants experiencing adverse events (AEs) | — | Recruiting | — | Progressive Familial Intrahepatic Cholestasis | 20 | 2031-04-30 | in 1,714 d | 2026-08-03 |
| A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing TreatmentNCT06850038observationalPercentage of participants with Alagille syndrome (ALGS) who are treated with odevixibat and undergo biliary diversion surgery or liver transplantation. | — | Recruiting | — | Alagille Syndrome | 30 | 2030-11-30 | in 1,563 d | 2026-08-03 |
| A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain TumoursNCT07441707Percentage of participants experiencing Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)Open-label · Treatment | Phase 1 | Recruiting | Drug: Tovorafenib | Low-grade Glioma | 6 | 2030-07-31 | in 1,441 d | 2026-07-30 |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisNCT06016842Event-free survivalRandomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Elafibranor · Other: Matched 80 mg placebo | Primary Biliary Cholangitis (PBC) | 276 | 2029-05-31 | in 1,015 d | 2026-08-03 |
| A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.NCT04752774Percentage of participants with treatment emergent adverse events (TEAEs).Randomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Biological: Corabotase, Dysport · Drug: Placebo | Spasticity | 240 | 2029-03-30 | in 953 d | 2026-07-28 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid TumoursNCT07213817Phase Ia: Percentage of participants with dose limiting toxicity (DLT)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: IPN60300 | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 114 | 2028-10-30 | in 802 d | 2026-07-30 |
| A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid TumoursNCT06833008Part A: Percentage of participants with dose limiting toxicity (DLT)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: IPN01195 | Advanced Solid Tumor | 85 | 2028-10-03 | in 775 d | 2026-07-30 |
| A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursNCT06305247Phase 1: Percentage of participants with dose limiting toxicity (DLT)Randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: IPN01194, IPN01194 | Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor | 36 | 2028-03-20 | in 578 d | 2026-07-30 |
| A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its DevelopmentNCT06055725observationalPercentage of participants at the Clinical Confirmation Visit (CCV) who have problematic spasticity and who the investigator considers would benefit from pharmacological therapy | — | Active, not recruiting | — | Spasticity as Sequela of Stroke | 1,058 | 2027-11-30 | in 467 d | 2026-07-08 |
| A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in AdultsNCT06625060Percentage of participants experiencing any Adverse Event (AEs) including treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse event of special interest (AESI) and AE leading to treatment discontinuationRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Biological: Corabotase, Corabotase dose A, Corabotase dose B · Other: Placebo | Episodic Migraine, Chronic Migraine | 641 | 2027-10-31 | in 437 d | 2026-07-28 |
| Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior TreatmentNCT07314164observationalDisease Control Rate (DCR) | — | Recruiting | — | Neuroendocrine Tumors | 150 | 2027-10-31 | in 437 d | 2026-07-01 |
| Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.NCT03647878observationalThe proportion of subjects with dose reduction of cabozantinib due to Serious Adverse Events/Adverse Events (SAEs/AEs) | — | Active, not recruiting | — | Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | 224 | 2027-09-30 | in 406 d | 2026-07-30 |
| Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)NCT04106349observationalTreatment line | — | Active, not recruiting | — | Advanced or Metastatic Renal Cell Carcinoma | 150 | 2027-03-31 | in 223 d | 2026-07-30 |
| A Study of IPN10200 for the Treatment of Cervical Dystonia in AdultsNCT06937931Change from Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Biological: Corabotase · Other: Placebo | Cervical Dystonia | 132 | 2027-03-26 | in 218 d | 2026-07-28 |
| A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)NCT06730061Percentage of participants with Alkaline phosphatase (ALP) <1.67x ULN, ALP decrease ≥15% and Total Bilirubin (TB) ≤ ULNOpen-label · Treatment | Phase 3 | Active, not recruiting | Drug: Elafibranor | Primary Biliary Cholangitis | 18 | 2026-12-17 | in 119 d | 2026-08-03 |
| A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsNCT07427797For North America: Percentage of participants responding to treatmentRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Biological: Corabotase, Placebo | Moderate to Severe Glabellar Lines | 300 | 2026-12-15 | in 117 d | 2026-07-28 |
| A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsNCT07435428For North America: Percentage of participants responding to treatmentRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Biological: Corabotase, Placebo | Moderate to Severe Glabellar Lines | 1,300 | 2026-12-15 | in 117 d | 2026-07-28 |
| A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial LinesNCT04821089Incidence of treatment emergent adverse events (TEAEs) at each doseRandomized · Quadruple-masked · Treatment | Phase 1/2 | Active, not recruiting | Biological: Corabotase, IPN10200 Placebo, Dysport | Moderate to Severe Upper Facial Lines | 727 | 2026-08-31 | in 11 d | 2026-07-28 |
| Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC)NCT07497724observationalPart A: Liver transplant-free survival (LTFS) | — | Active, not recruiting | — | PFIC - Progressive Familial Intrahepatic Cholestasis | 200 | 2026-08-01 | — | 2026-08-03 |
| A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in AdultsNCT06047457Change from baseline in monthly migraine days (MMD)Randomized · Double-masked · Prevention | Phase 3 | Active, not recruiting | Biological: Botulinum toxin type A, Botulinum toxin type A, Botulinum toxin type A, Botulinum toxin type A · Other: Placebo | Episodic Migraine | 751 | 2026-06-01actual | — | 2026-07-16 |
| CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb SpasticityNCT06245772observationalChange from baseline in the 5-item Carer Burden Scale (CBS) mean score | — | Active, not recruiting | — | Upper Limb Injury | 113 | 2026-05-29 | — | 2026-05-04 |
| A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in AdultsNCT06047444Change from baseline at week 24 in monthly migraine days (MMD)Randomized · Double-masked · Prevention | Phase 3 | Active, not recruiting | Biological: Botulinum toxin type A, Botulinum toxin type A, Botulinum toxin type A, Botulinum toxin type A · Other: Placebo | Chronic Migraine | 759 | 2026-05-28actual | — | 2026-07-16 |
| Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)NCT04526665results2024-09-05Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Elafibranor 80mg, Placebo | Primary Biliary Cirrhosis | 161 | 2023-06-01actual | — | 2026-08-04 |
| Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two TherapiesNCT07282548observationalReal-world Objective Response Rate (rwORR) stratified by EZH2 mutation status. | — | Withdrawnsponsor's stated reason: Withdrawn prior to enrolment after review of updated safety data | — | Follicular Lymphoma | 0 | 2031-06-30 | in 1,775 d | 2026-04-29 |
| A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.NCT06383403Percentage of participants with normalisation of Alkaline Phosphate (ALP) LevelsRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Elafibranor · Other: Placebo | Primary Biliary Cholangitis | 92 | 2026-06-16actual | — | 2026-07-09 |
| Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer TreatmentNCT05377684observationalProportion of participants reaching a clinically significant change in the global Quality of Life (QoL) score. | — | Completed | — | Early-stage Breast Cancer | 450 | 2026-06-04actual | — | 2026-07-10 |
| A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in SpainNCT07191704observationalPercentage of Participants with at least One Variant in PFIC-Related Genes | — | Completed | — | PFIC - Progressive Familial Intrahepatic Cholestasis | 150 | 2026-06-03actual | — | 2026-08-03 |
| Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With OsteosarcomaNCT06341712Progression-free Survival (PFS) assessed by Blinded Independent Radiology Committee (BIRC)Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges | Drug: Cabozantinib · Other: Best Supportive Care (BSC), Best Supportive Care (BSC) | Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults | 10 | 2026-02-27actual | — | 2026-03-31 |
| A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)NCT07049887observationalNumber of Nocturnal Scratch Events | — | Completed | — | Primary Biliary Cholangitis | 30 | 2026-02-23actual | — | 2026-04-30 |
| A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single DoseNCT06908954Maximum observed plasma drug concentration (Cmax)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Palovarotene, Palovarotene, Palovarotene | Hepatic Impairment, Healthy | 31 | 2026-02-06actual | — | 2026-04-30 |
| A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in AdultsNCT05361434observationalOverall survival (OS) rate (death of any cause) from the start of cabozantinib in combination with nivolumab. | — | Completed | — | Advanced Renal Cell Carcinoma | 311 | 2025-10-20actual | — | 2026-06-01 |
| A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.NCT04936542results2026-07-09Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) From Injection to 12 WeeksRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: AboBoNT-A, OnaBoNT-A | Upper Limb Spasticity | 464 | 2025-08-26actual | — | 2026-07-09 |
| Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.NCT05224349observationalChange from baseline of Disability Assessment Scale (DAS) score in Principle Target of Treatment (PTT) for the upper limb. | — | Completed | — | Post-Stroke Chronic Upper Limb Spasticity | 121 | 2025-04-09actual | — | 2025-08-01 |
| Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in ChinaNCT05431803observationalPercentage of participants achieving full biochemical control | — | Completed | — | Acromegaly | 129 | 2024-12-13actual | — | 2025-01-31 |
| A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and AcromegalyNCT06253897observationalQualitative interview: patients' injection experiences and satisfaction with the Ipsen lanreotide syringe and with the Pharmathen lanreotide syringe; | — | Completed | — | Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly | 20 | 2024-12-06actual | — | 2024-12-24 |
| A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.NCT05027802results2025-06-13Number of Participants With All Treatment-emergent Adverse Events (TEAEs), Serious and Non-serious Treatment-emergent Adverse Events and Serious and Non-serious Treatment-related Treatment-emergent Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Palovarotene | Fibrodysplasia Ossificans Progressiva (FOP) | 61 | 2024-11-30actual | — | 2025-06-22 |
| A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in ItalyNCT05759273observationalPercentage of Participants Naive to Androgen Deprivation Therapy (ADT), Non-naive to ADT and Castrated | — | Completed | — | Prostate Cancer | 167 | 2024-09-30actual | — | 2024-11-01 |
| Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the ProstateNCT05590793results2025-09-09Percentage of Participants Who Achieved Castrate Levels of Serum Testosterone on Day 29Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Triptorelin pamoate (embonate) salt | Advanced Prostate Cancer, Metastatic Prostate Cancer, Locally Advanced Prostate Cancer | 195 | 2024-08-20actual | — | 2025-09-09 |
| Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the ProstateNCT05458856results2025-07-23Percentage of Participants Who Maintained Castrate Levels of Serum Testosterone During the StudyOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Triptorelin embonate 22.5 mg | Prostate Cancer | 147 | 2024-07-08actual | — | 2025-07-25 |
| A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the PancreasNCT05383352Maximum (peak) plasma drug concentration (Cmax) of encapsulated irinotecan for Test relative to and Reference productRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Irinotecan liposome injection, Irinotecan liposome injection, Irinotecan liposome injection, Irinotecan liposome injection, Folinic Acid, 5-Fluorouracil | Metastatic Pancreatic Adenocarcinoma | 177 | 2024-05-27actual | — | 2025-04-30 |
| Post-marketing Surveillance on the Safety of CabometyxTM in Korean PatientsNCT03776123observationalNumber of patients experiencing Adverse Events (AEs)/ Serious Adverse Events (SAEs) after Cabometyx™ administration | — | Completed | — | Renal Cell Carcinoma, Hepatocellular Carcinoma, Differentiated Thyroid Carcinoma | 347 | 2024-03-26actual | — | 2024-05-29 |
| A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NETNCT05922579observationalAttribute importance | — | Terminatedsponsor's stated reason: Significant and complex challenges had since been identified during recent testing phases. After their assessment, Ipsendecided to discontinue development of this motorized device in order to not burden participants. | — | Neuroendocrine Tumors | 191 | 2023-12-01actual | — | 2024-02-29 |
| Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in ChinaNCT05184231observationalOverall patient satisfaction with SSA treatment. | — | Withdrawnsponsor's stated reason: Study wasn't feasible anymore. It was withdrawn on 13 Jan 2023. | — | Acromegaly | 0 | Oct 2023 | — | 2023-03-17 |
| Study to Predict Lanreotide-induced Disease Activity Normalization in AcromegalyNCT04003519observationalProportion of subjects with normalization of centrally assessed age and sex adjusted IGF-I levels at visit 4 (about 12 months) after treatment start with lanreotide autogel. | — | Withdrawnsponsor's stated reason: Study timeline delay, low site feasibility and delay concerns due to COVID-19. | — | Acromegaly | 0 | 2023-06-30 | — | 2020-06-02 |
| A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.NCT05444933observationalDuration of treatment (DOT) of cabozantinib | — | Completed | — | Advanced Renal Cell Carcinoma | 252 | 2023-05-12actual | — | 2023-07-18 |
| Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint InhibitorsNCT03945773results2024-12-19Cohort A: Objective Response Rate (ORR) Assessed by Independent Central ReviewNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Cabozantinib | Locally Advanced or Metastatic Renal Cell Carcinoma | 127 | 2023-05-11actual | — | 2026-07-31 |
| Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.NCT04609800observationalOverall survival (OS) rate at 1 year after cabozantinib initiation | — | Withdrawnsponsor's stated reason: Unfavorable opinion of IRB/IEC | — | Renal Cell Carcinoma | 0 | 2023-05-10 | — | 2020-12-21 |
| Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical PracticeNCT03895463observationalProgression-Free Survival (PFS) | — | Withdrawnsponsor's stated reason: Reassessment of study feasibility | — | Neuroendocrine Tumors | 0 | 2023-03-26 | — | 2020-11-05 |
| A Study to Collect Participants Experience of Living With Adult Upper Limb (AUL) Spasticity and to Assess the Arm Activity Measure (ArmA)NCT05546190observationalNumber of participants answering to the questionnaire: for Part 1 15/15 subject | — | Completed | — | Spastic Hemiparesis, Muscle Spasticity | 25 | 2023-03-23actual | — | 2023-04-18 |
| Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy ParticipantsNCT05543369Noncompartmental Pharmacokinetics (PK) of Elafibranor and its Metabolite GFT1007: Area Under the Concentration-time Curve Over the Dosing Interval from Time 0 to 24 hours(AUCτ)Non-randomized · Open-label · Other | Phase 1 | Completed | Drug: Elafibranor | Healthy Volunteers | 48 | 2023-03-10actual | — | 2025-02-20 |
| A Single Centre, Prospective, Observational Study to Assess the Use of the Rehabilitation Tool, GripAble, in Patients With Upper Limb Spasticity Receiving Botulinum Toxin-A (BoNT-A) in the United Kingdom (UK).NCT05169775observationalMean Physician Global Assessment (PGA) of treatment response scores in patients receiving BoNT-A for ULS during routine clinical practice. | — | Completed | — | Upper Limb Spasticity (ULS) | 16 | 2023-01-04actual | — | 2025-09-19 |
| A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single TabletNCT05564208Pharmacokinetics (PK) of Elafibranor: Area Under the Plasma Concentration Time Curve From Zero to the Last Quantifiable Concentration (AUC0-t)Randomized · Open-label · Other | Phase 1 | Completed | Drug: elafibranor, elafibranor | Healthy Participants | 34 | 2022-12-30actual | — | 2025-02-20 |
| Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.NCT04593420observationalProportion of subjects treated continuously with triptorelin for the 12 months | — | Completed | — | Prostate Cancer | 817 | 2022-12-08actual | — | 2022-12-21 |
| Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines.NCT04736745Incidence of the Treatment-Emergent Adverse Events (TEAEs) at each dose for dose escalationRandomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor terminated the study due to strategic considerations | Biological: IPN59011, Azzalure · Drug: Placebo | Moderate Upper Facial Lines, Severe Upper Facial Lines | 56 | 2022-10-28actual | — | 2023-07-14 |
| A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.NCT05029622results2024-05-28Percentage of Participants With Luteinising Hormone (LH) SuppressionOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Triptorelin Pamoate | Central Precocious Puberty | 66 | 2022-08-21actual | — | 2025-02-19 |
| Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life CohortNCT04050527observationalSubject centred Goal Attainment Scaling Leg T score (GASleg T) | — | Completed | — | Adult Lower Limb Spasticity | 438 | 2022-07-29actual | — | 2022-08-05 |
| A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine TreatmentNCT04083235results2024-03-13Overall Survival (OS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Irinotecan Liposomal Injection, Oxaliplatin, 5Fluorouracil, Leucovorin, Nab-paclitaxel, Gemcitabine | Metastatic Adenocarcinoma of the Pancreas | 770 | 2022-07-23actual | — | 2026-04-20 |
| Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing CombinationNCT04957160observationalDescription of the treatment sequence pathway from 1L up to 2L for patients with aRCC | — | Completed | — | Advanced Renal Cell Carcinoma (aRCC) | 281 | 2022-06-15actual | — | 2024-12-17 |
| Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsNCT04852679results2024-10-01Clinical Benefit Rate (CBR) of Tumour Response Assessed by Blinded Independent Central Review (BICR) at Week 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Lanreotide autogel | Gastroenteropancreatic Neuroendocrine Tumor | 43 | 2022-06-10actual | — | 2024-10-01 |
| United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration SettingNCT04649580observationalPatient preferences of treatment administration setting (homecare or hospital) | — | Completed | — | Neuroendocrine Tumours (NET) | 80 | 2022-06-05actual | — | 2024-12-17 |
| Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell CarcinomaNCT03419572observationalThe proportion of subjects with dose modifications due to AEs | — | Completed | Other: Data collection | Renal Cell Carcinoma | 689 | 2022-05-19actual | — | 2022-08-15 |
| A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male ParticipantsNCT04970407results2024-08-01Change From Baseline in Adjusted Mean (AM) Percentage (%) of CMAP Total Amplitude at Week 28Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: Botulinum toxin type A, Botulinum toxin type A, Botulinum toxin type A | Healthy Participants | 45 | 2022-03-16actual | — | 2025-02-19 |
| Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETsNCT02592707results2023-07-19Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Terminated (Due to small number of ongoing patients. Patients ongoing at time of termination could choose to join study D-FR-01072-004 for long term follow-up. | Drug: Satoreotide tetraxetan · Other: Amino acid solution, Antiemetic | Neuroendocrine Tumors | 40 | 2022-02-22actual | — | 2023-07-19 |
| Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.NCT04736602results2024-08-01Percentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) StimulationOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Triptorelin pamoate 15mg | Central Precocious Puberty | 32 | 2022-02-09actual | — | 2024-08-01 |
| Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung CancerNCT03088813results2023-10-17Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Irinotecan liposome injection, Topotecan | Small Cell Lung Cancer | 491 | 2022-02-08actual | — | 2025-02-19 |
| Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinANCT04446702observationalAverage total dose injected during all sessions of Dysport® in ULS +/- LLS | — | Completed | — | Spasticity | 200 | 2021-12-10actual | — | 2021-12-16 |
| Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.NCT04632199Incidence of Treatment-emergent adverse eventsRandomized · Open-label · Diagnostic | Phase 1 | Withdrawnsponsor's stated reason: Business decision not related to any safety or tolerability concern | Drug: 111In-IPN01087 Low dose, 111In-IPN01087 High dose | Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | 0 | 2021-12-10 | — | 2022-08-24 |
| Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETsNCT02630654observationalNumber of Participants With Progression Free Survival | — | Completed | Other: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician. | Gastroenteropancreatic Neuroendocrine Tumors | 404 | 2021-11-09actual | — | 2021-12-07 |
| Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type ANCT04340336observationalAverage total dose of BoNT-A | — | Completed | — | Spasticity | 150 | 2021-10-31actual | — | 2022-03-16 |
| To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer PatientsNCT03017313observationalPercentage of patients for whom the initial LHRH prescription (the prescription at the baseline visit) has been renewed at first follow-up visit (same type, same formulation). | — | Completed | Drug: LHRH analogues | Prostate Cancer | 510 | 2021-06-14actual | — | 2021-06-24 |
| A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal SpasticityNCT04604379observationalAverage total dose of AboBoNT-A for focal upper limb and/or lower limb spasticity per treatment session | — | Completed | — | Upper and/or Lower Limb Focal Spasticity | 123 | 2021-05-28actual | — | 2021-06-21 |
| Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.NCT03947762observationalProgression-free survival (PFS) rate at 24 months | — | Terminatedsponsor's stated reason: Low enrollment | — | Pancreatic Neuroendocrine Tumor | 54 | 2021-04-30actual | — | 2021-06-14 |
| An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.NCT04665323observationalQuality of life of people living with FOP and their family members, measured using the EuroQol health-related quality of life (QoL) questionnaire (EQ-5D-5L) | — | Completed | — | Fibrodysplasia Ossificans Progressiva | 411 | 2021-04-30actual | — | 2021-05-21 |
| A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.NCT04396704observationalAverage Goal Attainment Scale (GAS T) score 6 weeks | — | Completed | — | Spasticity Related to Any Cause Except Cerebral Palsy | 114 | 2021-03-30actual | — | 2021-05-21 |
| Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic AdenocarcinomaNCT02551991results2022-10-10Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: nal-IRI, 5 fluorouracil, Leucovorin, Oxaliplatin | Pancreatic Cancer | 56 | 2021-02-15actual | — | 2022-10-10 |
| Dysport in Vulvodynia Phase II StudyNCT03598777results2021-12-09Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the DB Treatment Period (Stage 1)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: lack of efficacy | Biological: Botulinum toxin type A · Drug: Placebo | Vulvodynia | 60 | 2021-01-21actual | — | 2021-12-09 |
| Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid TumoursNCT03894540results2021-11-22Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) in Part ANon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Following an internal portfolio review, Ipsen has made the decision to terminate study D-US-60090-001. Ipsen would like to highlight that early termination was not due to any safety or tolerability issues with IPN60090 | Drug: IPN60090, pembrolizumab, paclitaxel, IPN60090 single administration | Solid Tumor | 22 | 2020-12-21actual | — | 2022-09-13 |
| Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in EnglandNCT04637204observationalDuration of therapy for the index treatments of interest stratified by line of therapy (LoT) | — | Completed | Drug: Cabozantinib, Axitinib | Renal Cell Carcinoma | 1,540 | 2020-12-11actual | — | 2021-02-01 |
| Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb SpasticityNCT03017729observationalCumulated GAS T score | — | Completed | Biological: Botulinum toxin type A | Lower Limb Spasticity | 242 | 2020-11-30actual | — | 2020-12-19 |
| Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)NCT03689673observationalMedian time to relapse according to the patients with different maintenance Etiasa® daily dose | — | Completed | Other: Data collection | Ulcerative Colitis | 607 | 2020-11-16actual | — | 2021-02-02 |
| Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.NCT04649632observationalMean time to next injection per brand | — | Completed | — | Post Stroke Spasticity | 451 | 2020-09-18actual | — | 2020-12-02 |
| Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint InhibitorsNCT04353765observational6 months Real-World Response Rate | — | Completed | Drug: Cabozantinib monotherapy, All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC | Locally Advanced or Metastatic Renal Cell Carcinoma | 247 | 2020-06-05actual | — | 2021-11-17 |
| Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide AutogelNCT03562091observationalAbsolute variation on the score (standardized on a scale from 0 to 100) of the 3 targeted dimensions (disease, treatments and supportive care) of the self-administered Quality of Life Questionnaire (QLQ) QLQINFO25 | — | Completed | Other: Data collection | Neuroendocrine Tumors | 115 | 2020-05-15actual | — | 2020-08-28 |
| Community-based Neuroendocrine Tumor (NET) Research StudyNCT02730104observationalTime to disease progression | — | Completed | — | Gastroenteropancreatic Neuroendocrine Tumors | 100 | 2020-05-13actual | — | 2020-06-26 |
| Spasticity and Treatment Satisfaction Among Stroke SurvivorsNCT03995524observationalDegree of functional limitations in daily life activities | — | Completed | — | Spasticity as Sequela of Stroke | 30 | 2020-05-12actual | — | 2020-06-01 |
| Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.NCT03525392results2023-12-12Phase 1: Number of Participants With Dose-Limiting Toxicities (DLT)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns | Drug: 177Lu-3BP-227 (also called 177Lu-IPN01087) | Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck, Bone Cancer, Advanced Cancer, Recurrent Disease, Metastatic Tumours | 14 | 2020-04-03actual | — | 2023-12-12 |
| Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursNCT02683941results2021-10-29Median Progression-Free Survival (PFS) Time in Subjects Randomised to Lanreotide in the Double-Blind Phase or Open-Label Treatment Phase, Assessed by Central ReviewRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: National Comprehensive Cancer Network \& European Neuroendocrine Tumor Society guidelines (2015/2016) led to prescription of somatostatin analogues (SSAs) in this setting, thereby limiting recruitment. | Drug: Lanreotide (Autogel formulation), Placebo, Best Supportive Care | Neuroendocrine Tumors in Lung | 77 | 2020-02-28actual | — | 2022-07-06 |
| Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist TherapyNCT03516110observationalQuality of Life (QOL) as evaluated by Quality of Life Questionnaire-Elderly 14 items (QLQ-ELD-14) | — | Completed | Other: Data collection | Prostate Cancer | 831 | 2020-02-28actual | — | 2026-01-23 |
| Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing ColonoscopyNCT03008460results2021-03-02Percentage of Subjects With Successful Overall Colon Preparation, Assessed With the Cleansing Score (4-point Scale)Randomized · Single-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Eziclen®/Izinova®, Klean-Prep® | Digestive System Disease | 250 | 2020-02-24actual | — | 2021-03-02 |
| Validation of Patient Reported Outcome Measures for Use in Hallux ValgusNCT03846687observationalConcept elicitation (CE) of mFFI | — | Completed | — | Hallux Valgus | 21 | 2020-01-15actual | — | 2020-01-27 |
| Dysport in Hallux Abducto Valgus (HAV) Phase IIaNCT03569098results2021-07-02Least Square (LS) Mean Change From Baseline in the Daily Numeric Pain Rating Scale (NPRS) Score at Week 8Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Hallux Abducto Valgus | 186 | 2019-12-17actual | — | 2021-07-02 |
| Dysport in Post-Surgical NeuralgiaNCT03663101results2020-12-04Time to Onset of Effect in the Spontaneous Numerical Rating Scale (NRS) ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lidocaine, Placebo, Placebo · Biological: Botulinum toxin type A | Chronic Scar Pain | 16 | 2019-11-08actual | — | 2021-01-12 |
| Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mgNCT02651987results2020-12-30Median Progression Free Survival (PFS)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lanreotide autogel 120 mg | Pancreatic Tumours, Midgut Neuroendocrine Tumours | 99 | 2019-10-16actual | — | 2022-10-03 |
| Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)NCT03773133results2020-10-30Maximum Tolerated Cumulative Activity - Phase IOpen-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: High number of screen failures | Drug: Satoreotide tetraxetan, Satoreotide trizoxetan | Small Cell Lung Cancer and Breast Cancer | 9 | 2019-10-10actual | — | 2022-09-13 |
| Validation of Patient Reported Outcome Measures for Use in VulvodyniaNCT03770169observationalValidation of mVPAQ | — | Completed | — | Vulvodynia | 20 | 2019-09-19actual | — | 2019-10-28 |
| A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.NCT01753297results2020-12-09Number of Subjects With BR EventsRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Triptorelin 11.25 mg | Prostate Cancer | 226 | 2019-09-09actual | — | 2020-12-09 |
| Validation of the Spasticity Related Quality of Life QuestionnaireNCT03442660Validation of SQOL-6D in upper limb spasticityOpen-label · Other | Not applicable | Completed | Other: Data collection | Spasticity, Muscle | 104 | 2019-08-09actual | — | 2019-09-30 |
| A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UKNCT03696407observationalPositioning of cabozantinib in the treatment pathway | — | Completed | — | Advanced Renal Cell Carcinoma | 108 | 2019-08-01actual | — | 2020-11-05 |
| To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)NCT03220217results2021-01-14Relative Lesion Counts Presented by Combination of Injected Peptide/Radioactivity Dose RangesRandomized · Single-masked · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Satoreotide trizoxetan 5-20μg, Satoreotide trizoxetan 30-45μg | Gastro-Enteropancreatic Neuroendocrine Tumor | 29 | 2019-07-25actual | — | 2021-01-14 |
| Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCCNCT03699579observationalMedication usage | — | Completed | — | Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma | 28 | 2019-06-23actual | — | 2019-08-28 |
| Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.NCT03744585observationalDuration of treatment exposure | — | Completed | — | Renal Cell Carcinoma | 450 | 2019-06-07actual | — | 2019-07-26 |
| Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate CancerNCT02238366observationalPercentage of patients for whom the initial Gonadotropin-releasing Hormone (GnRH) analogue formulation has been renewed. | — | Completed | Drug: triptorelin | Prostate Cancer | 368 | 2019-06-06actual | — | 2019-07-25 |
| Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life PracticeNCT02454803observationalPatient centred goal attainment will be assessed using the cumulated Goal Attainment Scale Total Score (GAS T score). | — | Completed | — | Upper Limb Spasticity | 1,004 | 2019-06-03actual | — | 2019-08-05 |
| Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With EndometriosisNCT03232281results2021-10-14Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at Week 12Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Triptorelin Pamoate PR 3-month, Triptorelin Acetate PR 1-month | Endometriosis | 300 | 2019-05-17actual | — | 2021-10-14 |
| Efficacy, Safety and Tolerability of a New Bowel Cleansing Preparation (BLI800) in Adult Subjects Undergoing ColonoscopyNCT03562884The proportion of subjects with successful overall preparation based on a centrally assessed global BBPS score (for all segments) ≥ 6 (centralised assessment).Randomized · Single-masked · Diagnostic | Phase 3 | Completed | Drug: BLI800, Fortrans® | Diagnosis Disease | 297 | 2019-04-28actual | — | 2019-05-30 |
| Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in AdultsNCT02704091results2020-04-24Time to RecoveryRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Smecta, Smecta placebo | Acute Diarrhoea | 858 | 2019-04-08actual | — | 2020-11-05 |
| Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.NCT02698410results2020-10-01Disease Control Rate (DCR) Assessed Locally at Month 9Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lanreotide (Autogel formulation) and Temozolomide | Neuroendocrine Tumours | 40 | 2019-02-08actual | — | 2020-10-01 |
| Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast CancerNCT03697551results2020-09-07Percentage of Subjects With Sufficiently Avid Lesion(s) Identified as a sstr2 Positive Lesion (Co-Primary Endpoint)Open-label · DiagnosticStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 2 | Terminatedsponsor's stated reason: Recruitment challenges and not due to safety concerns. | Drug: Satoreotide trizoxetan | Breast Cancer | 4 | 2019-02-06actual | — | 2020-09-07 |
| Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1NCT02660138results2021-06-16Mean Change From Baseline in Weekly Number of UI Episodes at Week 6 of DBPC CycleRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Low recruitment of patients | Biological: Botulinum toxin type A, Botulinum toxin type A · Drug: Placebo, Placebo | Urinary Incontinence, Overactive Bladder | 227 | 2018-11-09actual | — | 2022-09-28 |
| Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2NCT02660359results2021-06-16Mean Change From Baseline in Weekly Number of UI Episodes at Week 6 of DBPC CycleRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Slow recruitment of patients | Biological: Botulinum toxin type A, Botulinum toxin type A · Drug: Placebo, Placebo | Urinary Incontinence, Overactive Bladder | 258 | 2018-11-09actual | — | 2022-09-28 |
| MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentNCT01770353results2019-10-28Pilot Phase: Tumour Levels of Irinotecan and SN-38 at Cycle 1 Day 4Non-randomized · Open-label · OtherStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 1 | Completed | Drug: Ferumoxytol, MM-398 | Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis | 45 | 2018-10-02actual | — | 2019-11-27 |
| Validation Study of the SAGIT® Instrument in AcromegalyNCT02539927observationalDefine and validate the scoring of the SAGIT® instrument | — | Completed | — | Acromegaly | 227 | 2018-09-03actual | — | 2018-11-01 |
| Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) AnaloguesNCT02542501observationalThe number of patients having Lower Urinary Tract Symptoms (LUTS) at baseline. | — | Completed | — | Prostate Cancer | 470 | 2018-07-21actual | — | 2018-12-21 |
| A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 MonthsNCT01942369observationalChanges in the intensity of specific endometriosis symptoms from baseline pre-surgery | — | Completed | Drug: Triptorelin Acetate 3.75mg intramuscular injection | Deep Infiltrating Endometriosis (DIE) | 402 | 2018-07-13actual | — | 2018-12-06 |
| Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.NCT02396966observationalAcromegaly quality of life (AcroQol) questionnaire | — | Completed | — | Acromegaly | 152 | May 2018actual | — | 2018-12-21 |
| Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)NCT03017690observationalThe total time for product preparation and administration | — | Completed | — | Gastroenteropancreatic Neuroendocrine Tumor | 22 | 2018-05-30actual | — | 2018-12-21 |
| Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in SpainNCT03220087observationalUse of resources and costs in patients with controlled or uncontrolled CS | — | Completed | Other: Data collection | Neuroendocrine Tumors | 142 | 2018-04-30actual | — | 2018-12-21 |
| Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal FunctionNCT03442725results2019-09-13Maximum Plasma Concentration (Cmax) of Total Telotristat Ethyl, LP-778902 and LP-951757Non-randomized · Open-label · Basic scienceStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 1 | Completed | Drug: Telotristat etiprate | Renal Impairment | 16 | 2018-04-27actual | — | 2020-04-08 |
| Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)NCT02969356results2019-06-04Percentage of Responder Participants at Week 6 After the Second Injection, According to Composite Active Range of Motion (AROM) in the Primary TT LimbOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: Botulinum toxin type A · Other: GSC | Spastic Hemiparesis | 157 | 2018-04-26actual | — | 2025-02-19 |
| RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following StrokeNCT02020980observationalChange in Pain relief on Numeric Rating Scale | — | Completed | Biological: Botulinum toxin type A | Lower Limb Spasticity | 186 | 2018-03-05actual | — | 2019-07-29 |
| Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation)NCT01840475observationalComparison of modified Ashworth scale (MAS) between patients with early start of treatment and patients with late start of treatment in the overall population (naive and pre-treated). | — | Completed | — | Post-stroke Arm Spasticity | 302 | 2018-02-06actual | — | 2020-03-31 |
| Quality of Life in Patients With Inoperable Malignant Bowel ObstructionNCT02365584results2019-10-01Least Squares (LS) Mean Area Under Curve (AUC) of Edmonton Symptom Assessment System (ESAS) Total Scores Collected for the First 7 Days; Full Analysis Set (FAS)Randomized · Open-label · Supportive careStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was terminated early due to insufficient recruitment. | Drug: lanreotide (Autogel formulation) | Intestinal Obstruction | 43 | 2018-01-16actual | — | 2019-11-22 |
| Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.NCT02630641observationalChange in quality of life of the patient. | — | Completed | Drug: Gonadotropin-releasing Hormone (GnRH) agonist therapy | Prostate Cancer | 1,000 | Nov 2017actual | — | 2023-05-12 |
| Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With AcromegalyNCT02396953results2019-04-25Determination of the Maximum Tolerated Dose (MTD) by Number of Subjects With DLTs.Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Lanreotide PRF | Acromegaly | 28 | 2017-11-28actual | — | 2019-04-25 |
| Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal ObstructionNCT02275338results2019-04-01Percentage of Responders Before or at Day 7Open-label · Supportive careStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lanreotide Autogel | Intestinal Obstruction | 52 | 2017-11-09actual | — | 2019-04-16 |
| Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine TumorsNCT03112694observationalResponse to treatment | — | Completed | Other: Data collection | Neuroendocrine Tumors | 93 | 2017-11-02actual | — | 2020-06-02 |
| Phase IV-Cervical Dystonia-INTEREST IN CD2NCT01753349observationalChange in subject's satisfaction using a 5-point Likert scale. | — | Completed | Biological: Botulinum toxin type A | Cervical Dystonia | 1,050 | Sep 2017actual | — | 2020-11-05 |
| Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic SubjectsNCT02807233observationalPercentage of subjects with a normal Insulin-like Growth Factor 1 (IGF-1) level in the assay before the study visit. | — | Completed | — | Acromegaly | 115 | Sep 2017actual | — | 2019-08-05 |
| Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In ChildrenNCT02106351results2019-12-24Mean Change From Baseline to TC 1, Week 6 in MAS Score in the TC 1 PTMGRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Botulinum toxin type A | Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children | 212 | 2017-09-21actual | — | 2022-09-28 |
| Study on the Use of Botulinum Toxin Type A in the Treatment of Chronic Post-stroke Spastic PatientsNCT02390206observationalChange in Goal Achievement Score (GAS). | — | Completed | — | Spasticity | 239 | 2017-08-28actual | — | 2017-10-02 |
| ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb SpasticityNCT02275312observationalChange in Goal Attainment Scale (GAS) score. | — | Completed | — | Spasticity | 110 | Jul 2017actual | — | 2019-08-16 |
| A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine TumoursNCT02788578observationalProgression Free Survival (PFS) rate according to the central reading using RECIST (Version 1.1) | — | Terminatedsponsor's stated reason: The study terminated prematurely due to insufficient recruitment. | — | Neuroendocrine Tumours | 40 | Jul 2017actual | — | 2018-12-21 |
| Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours PatientsNCT02075606results2019-06-07Assessment of Clinical Symptomatic ResponseOpen-label · DiagnosticStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 4 | Completed | Drug: lanreotide acetate | NeuroEndocrine Tumours | 50 | Jun 2017actual | — | 2019-06-07 |
| Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With AcromegalyNCT03045302results2019-03-08The Number of Subjects Who Were Growth Hormone (GH) Responders at Day 14 of the Treatment PeriodOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Early termination is a sponsor decision. No new safety signal or serious adverse event has been observed. | Drug: BIM23B065 | Acromegaly | 4 | 2017-05-17actual | — | 2019-03-08 |
| Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic DiarrhoeaNCT03045926results2019-03-11Mean Change From Baseline in Blood Lead Levels During the Treatment Period and Post-treatment Follow-up PeriodOpen-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Diosmectite (Smecta®) | Chronic Functional Diarrhea of Unknown Origin | 35 | 2017-05-09actual | — | 2019-04-05 |
| Eziclen Drug Utilisation in Real Life SettingNCT02630680observationalVolume of liquid intake | — | Completed | Drug: Eziclen®/Izinova® | Bowel Cleansing | 1,286 | 2017-04-25actual | — | 2019-01-07 |
| Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post StrokeNCT02384330observationalEstimate the cost of botulinum toxin utilization | — | Completed | — | Upper Limb Spasticity Post-Stroke | 57 | 2017-03-16actual | — | 2019-01-07 |
| Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine TumoursNCT02853422observationalSurvey on the clinical utility of the QLQ-GINET21, which the investigator is to complete for each patient enrolled | — | Completed | — | Gastrointestinal Neuroendocrine Tumours | 199 | Jan 2017actual | — | 2020-11-05 |
| A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth DisordersNCT00455728observationalNumber of participants with adverse events | — | Completed | — | Growth Hormone Disorders | 3,690 | Dec 2016actual | — | 2019-01-07 |
| Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETNCT02231762results2019-05-06Disease Control Rate (DCR) After 6 MonthsOpen-label · Treatment | Phase 2 | Completed | Drug: Lanreotide Autogel 120 mg, Temozolomide (TMZ) | Gastroenteropancreatic Neuroendocrine Tumors | 57 | Dec 2016actual | — | 2019-05-06 |
| Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyNCT02493517results2018-12-14Standardised Mean Change From Baseline in Age-adjusted IGF-1 Levels at the EOST/EW VisitRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Lanreotide Autogel®, Lanreotide Acetate | Acromegaly | 128 | Nov 2016actual | — | 2019-01-29 |
| Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine TumoursNCT02788565observationalProportion of subjects with injection problems according to the subject | — | Completed | — | Gastroenteropancreatic Neuroendocrine Tumours | 156 | Oct 2016actual | — | 2020-06-02 |
| Study to Document the Effectiveness of Dysport in Patients Suffering From Upper Limb Spasticity (ULS) After StrokeNCT02444494observationalChange in Investigator and patient Clinical Global Impression of Improvement (CGI-I) | — | Completed | — | Post Stroke Arm Spasticity | 108 | Sep 2016actual | — | 2018-12-21 |
| Somatuline Predictive Factors in Acromegaly and NETNCT01840449observationalChange in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects) | — | Completed | Drug: Somatuline Autogel® 60, 90 or 120 mg | Acromegaly, Neuroendocrine Tumours | 156 | Jul 2016actual | — | 2019-01-14 |
| Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®NCT02353897observationalTo assess patient satisfaction regarding GL after three injection cycles of Dysport. | — | Completed | — | Glabellar Lines | 150 | Jul 2016actual | — | 2020-11-05 |
| Dysport in the Treatment of Glabellar Lines in Chinese SubjectsNCT02450526results2019-06-06Superiority Analysis of The Percentage of Responders Measured by the Investigator's Live Assessment (ILA) at Maximum Frown at Cycle 1, Day 29 (DB Period).Randomized · Triple-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A, Botulinum toxin type A · Drug: Placebo, Placebo | Glabellar Lines | 520 | Jul 2016actual | — | 2019-08-06 |
| Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy SubjectsNCT02683577results2017-11-28Assessment of Maximum Observed Plasma Drug Concentration (Cmax) for Telotristat Ethyl and Comparison Between Each HI Group and Healthy Control GroupOpen-label · Basic science | Phase 1 | Completed | Drug: telotristat etiprate | Hepatic Impairment | 24 | Jul 2016actual | — | 2019-01-25 |
| Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease PatientsNCT02231580results2018-01-29Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs).Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: The study was terminated due to subject recruitment problems. | Drug: BN82451B, Placebo | Huntington's Disease | 17 | 2016-03-31actual | — | 2019-01-15 |
| Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity ProgressionNCT02321436results2017-06-26Time Between the Initial Injection and the Appearance of Reinjection Criteria as Evaluated by the Modified Ashworth Scale (MAS) and Spasticity SymptomsRandomized · Double-masked · Treatment | Phase 4 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Stroke, Upper Limb Spasticity | 42 | Mar 2016actual | — | 2022-09-28 |
| Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mgNCT02698384observationalPercentage of subjects who achieve a safe concentration of random Growth Hormone (GH) (≤2.5 ng/mL) and normal age and sex-matched Insulin-like Growth Factor-1 (IGF-1) concentration of the monotherapy phase. | — | Terminatedsponsor's stated reason: The study was terminated early due to insufficient potential for recruitment. | — | Acromegaly | 4 | Jan 2016actual | — | 2018-12-21 |
| Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine TumourNCT00842348results2017-02-17Adverse EventsOpen-label · Treatment | Phase 3 | Completed | Drug: lanreotide (Autogel formulation) | Non Functioning Entero-pancreatic Endocrine Tumour | 89 | Dec 2015actual | — | 2022-10-12 |
| A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After StrokeNCT01239628observationalDocumentation of the injection intervals | — | Terminatedsponsor's stated reason: Participant enrolment was lower than expected | — | Upper Limb Spasticity After Stroke | 45 | Dec 2015actual | — | 2020-03-31 |
| Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing ColonoscopyNCT02321462results2019-02-27Adjusted Percentage of Patients With Successful Overall Colon Preparation, Assessed by the Global Score of the Boston Bowel Preparation Scale (BBPS).Randomized · Single-masked · Diagnostic | Phase 3 | Completed | Drug: Eziclen, Fortrans® | Bowel Cleansing | 296 | Dec 2015actual | — | 2019-03-04 |
| Quality of Life of Patients With Locally Advanced and Metastatic Prostate CancerNCT02853409observationalQuality of life evolution, using the validated Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) | — | Completed | — | Prostate Cancer | 628 | Dec 2015actual | — | 2018-12-21 |
| Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational StudyNCT00686348observationalAssess the safety & effectiveness, as measured by IGF-1 & GH levels, of Somatuline® Depot Injection when administered by a health care professional, the patient, the patient's partner or parent/guardian as part of their routine acromegaly care. | — | Completed | — | Acromegaly | 260 | Nov 2015actual | — | 2019-01-11 |
| Longitudinal Study for Treatment With Botulinum Toxin A Injections in naïve and Pre-treated Patients Suffering From Cervical Dystonia [CD-NIS-Longterm]NCT01840462observationalChange in Tsui scores | — | Completed | — | Cervical Dystonia | 372 | Nov 2015actual | — | 2019-01-14 |
| Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical DystoniaNCT01753336results2017-05-04TWSTRS Total Score at Week 4 and Week 12 for Treatment Cycles 1, 2 and 3.Open-label · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A | Cervical Dystonia | 112 | Oct 2015actual | — | 2019-08-07 |
| Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar LinesNCT02493946results2019-05-28The Percentage of Responders at Day 29 Cycle 1 as Measured by Investigator's Live Assessment (ILA) of Glabellar Lines at Maximum Frown: DB PeriodRandomized · Double-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Glabellar Lines | 600 | Oct 2015actual | — | 2022-09-28 |
| Predictive Factors StudyNCT02020499observationalChange in Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels from baseline | — | Terminatedsponsor's stated reason: Poor enrolment | Drug: Somatuline Autogel® (lanreotide) 60, 90, 120 mg. | Acromegaly | 5 | Sep 2015actual | — | 2019-01-14 |
| Programme of Acromegaly Screening in Patients With Associated Somatic DisordersNCT02020967results2021-04-28observationalPercentage of Participants Diagnosed With Acromegaly | — | Completed | Other: Non-interventional cross-sectional survey | Acromegaly | 367 | 2015-09-15actual | — | 2021-05-26 |
| 68Ga-OPS202 Study for Diagnostic Imaging of GEP NETNCT02162446results2019-10-02Number of Participants Reported With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Drug Reactions (ADRs)Open-label · Diagnostic | Phase 1/2 | Completed | Drug: satoreotide trizoxetan | Gastroenteropancreatic Neuroendocrine Tumors | 12 | Jun 2015actual | — | 2019-10-02 |
| Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate CancerNCT02057666results2021-04-23Time to Radiological Progression-Free Survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Development of tasquinimod in prostate cancer discontinued | Drug: Tasquinimod, Placebo | Prostatic Neoplasms, Castration-Resistant | 146 | May 2015actual | — | 2021-04-23 |
| Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up StudyNCT00909844results2017-05-01Percentage of Children With a Stabilisation or Regression of Tanner Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0)Open-label · Treatment | Phase 3 | Completed | Drug: Triptorelin (I.N.N.) | Precocious Puberty | 35 | Apr 2015actual | — | 2019-01-15 |
| Dysport® Adult Lower Limb Spasticity Follow-on StudyNCT01251367results2017-11-09Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A | Post-stroke Spasticity, Spasticity Post-Traumatic Brain Injury | 352 | Apr 2015actual | — | 2022-09-28 |
| EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive DisordersNCT02321475observationalPercentage of patients with increase of total medium FAM test score ≥1 after 3 months treatment | — | Completed | Drug: EGb761® | Cognitive Disorders | 54 | Apr 2015actual | — | 2020-03-31 |
| Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar LinesNCT02353871results2017-10-02The Proportion of Responders at Day 29 in the ILA of Glabellar Lines at Maximum Frown.Randomized · Double-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Moderate to Severe Glabellar Lines | 185 | Apr 2015actual | — | 2022-09-28 |
| Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical PracticeNCT01682148results2019-02-18Change From Baseline for Elbow Flexors Muscle Tone as Measured by the Modified Ashworth Scale (MAS) at Week 4Randomized · Single-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: The study was terminated early due to slow recruitment. | Biological: Botulinum toxin type A | Arm Spasticity | 100 | Mar 2015actual | — | 2022-09-27 |
| A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based ChemotherapyNCT01732549results2016-10-03Time to Radiological Progression Free Survival [PFS]Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Development of tasquinimod in prostate cancer discontinued | Drug: Tasquinimod, Placebo | Metastatic Castrate Resistant Prostate Cancer | 144 | Feb 2015actual | — | 2019-11-22 |
| The Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or OverNCT02321449observationalChange from baseline in quality of sleep questionnaire | — | Completed | — | Insomnia | 40 | Feb 2015actual | — | 2019-01-11 |
| Dysport® Pediatric Lower Limb Spasticity Follow-on StudyNCT01251380results2017-06-01Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Reported in the Double Blind (DB) + Open Label (OL) Period.Open-label · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A | Cerebral Palsy, Muscle Spasticity, Children | 216 | Jan 2015actual | — | 2022-09-28 |
| Dysport® Adult Upper Limb Spasticity Extension StudyNCT01313312results2017-06-07Assessment of the Long-term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A | Nervous System Disorders | 258 | Dec 2014actual | — | 2022-09-28 |
| Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate CancerNCT01374087results2017-02-23Biochemical Failure-free Survival (BFFS)Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Slow enrollment of patients. | Drug: Triptorelin 22.5 mg · Radiation: Brachytherapy | Prostate Cancer | 32 | Dec 2014actual | — | 2019-09-18 |
| A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric CancersNCT01743469results2018-05-07Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts).Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Tasquinimod, Tasquinimod, Tasquinimod, Tasquinimod | Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Metastatic Renal Cell Cancer, Advanced or Metastatic Gastric Carcinoma | 201 | Dec 2014actual | — | 2019-01-08 |
| Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital EndometriosisNCT03586063observationalSeverity of disease symptom menorrhagia (none-mild-moderate-severe) in different disease stages I, II, III in the Russian subject population scheduled for treatment with Diphereline 3.75 mg | — | Completed | Other: Data collection | Internal Endometriosis | 465 | 2014-12-24actual | — | 2018-07-13 |
| Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.NCT01753310results2017-03-16Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score at Week 4.Randomized · Double-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Cervical Dystonia | 134 | Oct 2014actual | — | 2019-08-07 |
| Study To Optimize Photodynamic Transurethral Resection of the Bladder (TUR-B) In Clinical PracticeNCT02012036observationalDetection rate | — | Completed | Drug: Hexvix | Photodynamic Transurethral Resection of the Bladder (TUR-B) | 400 | Jul 2014actual | — | 2019-08-16 |
| Study in Polish Acromegalic Patients Treated With Somatuline AutogelNCT01333384observationalPercentage variation of Insulin-like growth factor-1 (IGF-1) levels | — | Completed | — | Acromegaly | 150 | Jun 2014actual | — | 2019-01-07 |
| Description of Sign-and-symptom Associations at Acromegaly Diagnosis.NCT02012127observationalDescription of the most characteristic sign-and-symptom associations of acromegaly, collected by a patient questionnaire. | — | Completed | — | Acromegaly | 648 | Jun 2014actual | — | 2019-08-05 |
| IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of IncrelexNCT00747604observationalTo obtain long-term safety and efficacy data for Increlex® replacement therapy in children with growth failure | — | Terminatedsponsor's stated reason: Shortage of Increlex supply | Biological: mecasermin [rDNA origin] injection | Primary Insulin-like Growth Factor-1 Deficiency | 1,378 | May 2014actual | — | 2020-11-06 |
| A Long-term Observational Study Cohort in Patients With Advanced Prostate CancerNCT01383863observationalCastration-resistant prostate cancer (CRPC) | — | Completed | — | Advanced Prostate Cancer | 180 | May 2014actual | — | 2019-01-14 |
| SAGIT for Classification of Patients With Acromegaly in Clinical PracticeNCT02231593observationalNumber of acromegaly patients classified using SAGIT | — | Completed | Other: SAGIT | Acromegaly | 71 | May 2014actual | — | 2020-03-31 |
| Dysport® Pediatric Lower Limb Spasticity StudyNCT01249417results2017-02-03Change in MAS Score in the Gastrocnemius-soleus Complex (GSC) at the Ankle Joint of the (Most) Affected Lower LimbRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Cerebral Palsy, Muscle Spasticity, Children | 241 | Feb 2014actual | — | 2022-09-28 |
| GP Extended Action TriptorelinNCT01673984results2015-09-29Percentage of Participants Maintaining Biochemical CastrationRandomized · Open-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: The study was discontinued prematurely by the sponsor due to non-medical reasons | Drug: Decapeptyl® SR 22.5mg, Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg | Prostate Cancer | 27 | Feb 2014actual | — | 2025-05-23 |
| Dysport® Adult Lower Limb Spasticity StudyNCT01249404results2017-10-17Least Squares Mean Change From Baseline to Week 4 in the MAS Score in the Gastrocnemius-soleus Complex (GSC) (Knee Extended)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Leg Spasticity | 388 | Dec 2013actual | — | 2022-09-28 |
| DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical DystoniaNCT01314365observationalProportion of treatment responders using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) severity scale score | — | Completed | — | Cervical Dystonia | 350 | Nov 2013actual | — | 2020-11-05 |
| IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish PopulationNCT01676090observationalIGF-1 levels according to age, sex and pubertal stage in healthy paediatric volunteers | — | Terminatedsponsor's stated reason: Participant enrolment was lower than expected | — | IGF-1 Deficiency | 304 | Oct 2013actual | — | 2019-01-11 |
| Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate CancerNCT01715129results2015-10-28Percentage of Subjects Demonstrating Castration at Day 29 and Maintaining Castration at Day 183Open-label · Treatment | Phase 3 | Completed | Drug: Triptorelin Pamoate 11.25mg | Prostate Cancer | 126 | Oct 2013actual | — | 2019-12-09 |
| Dysport® Adult Upper Limb SpasticityNCT01313299results2015-10-23Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A, Botulinum toxin type A · Drug: Placebo | Nervous System Disorders | 243 | Sep 2013actual | — | 2022-09-28 |
| Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.NCT01562522Sufficient interest in participationRandomized · Open-label · Supportive care | Phase 2 | Terminatedsponsor's stated reason: Poor enrolment; only 6 subjects enrolled and they were all screen failures. | Other: Psychological counseling | Prostate Cancer | 6 | Jul 2013actual | — | 2019-11-07 |
| Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer PatientsNCT01313273results2015-08-14Progression-free SurvivalRandomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Poor enrolment | Drug: Lanreotide, non steroidal anti androgens and LHRH-a, Non steroidal anti androgens and LHRH-a | Prostate Cancer | 3 | Jun 2013actual | — | 2019-11-22 |
| An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid SyndromeNCT00774930results2016-02-09Percentage of Days With Subcutaneous Octreotide as Rescue MedicationRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Lanreotide, Placebo | Carcinoid Syndrome | 115 | May 2013actual | — | 2022-10-14 |
| Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)NCT01438801Peak serum IGF-1 level with GH (1.4 mg/m2/day) change from baseline.Open-label · Diagnostic | Phase 4 | Withdrawnsponsor's stated reason: Participant enrollment was not feasible | Drug: Nutropin [Somatropin (rDNA origin) for injection] | Idiopathic Short Stature | 0 | 2013-05-31 | — | 2019-08-05 |
| One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With MacroadenomaNCT01471405observationalProportion of patients maintained on medical treatment with lanreotide Autogel | — | Completed | — | Acromegaly | 54 | May 2013actual | — | 2019-01-11 |
| Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant StateNCT01560858observationalPrior treatment before progression to advanced or metastatic disease. | — | Completed | — | Prostate Cancer | 407 | May 2013actual | — | 2019-01-25 |
| Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine TumoursNCT00353496results2015-02-18Progression-Free Survival (PFS)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: lanreotide (Autogel formulation), Placebo | Endocrine Tumors | 264 | Apr 2013actual | — | 2025-03-05 |
| Non Interventional Post Marketing Programme in Neuroendocrine TumoursNCT00747786observationalsafety and local tolerability of Somatuline Autogel when administered by patients or their partners or from a healthcare professional | — | Completed | — | Neuroendocrine Tumors | 40 | Apr 2013actual | — | 2019-01-07 |
| A Study of the Potential Risk Factors Linked to the Development of Severe Forms of EndometriosisNCT01351051observationalFactors associated with endometrioma and/or deep infiltrating endometriosis using retrospective data collection and patient questionnaire. | — | Completed | — | Endometriosis | 1,008 | Apr 2013actual | — | 2019-01-14 |
| Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic SubjectsNCT00701363results2015-12-14Percentage of Subjects Having Maintained Their Injection Interval Schedule of Six Weeks or Increased Their Injection Interval to Eight Weeks Whilst Keeping Their Normalised Insulin Growth Factor (IGF-1) Levels (Age and Sex Adjusted)Open-label · Treatment | Phase 4 | Completed | Drug: Lanreotide Autogel 120 mg | Acromegaly | 124 | Mar 2013actual | — | 2019-01-29 |
| Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple SclerosisNCT01357980results2014-09-01Daily Incontinence Episode Frequency (IEF)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Detrusor Muscle Hyperactivity | 47 | Mar 2013actual | — | 2022-09-27 |
| A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of DiarrheaNCT01234168observationalSubject's overall satisfaction regarding control of diarrhea | — | Completed | — | Neuroendocrine Tumors, Carcinoid Syndrome | 340 | Dec 2012actual | — | 2020-11-05 |
| Non Interventional Post Marketing Programme in AcromegalyNCT00747500observationalsafety and local tolerability of Somatuline Autogel when administered by patients or their partners or from a healthcare professional | — | Completed | — | Acromegaly | 42 | Sep 2012actual | — | 2019-01-07 |
| Adult Subjects Suffering From Lower Limb Spasticity Following StrokeNCT01444794observationalResponder rate as defined by the achievement of the primary goal from the Goal Attainment Scale (GAS). | — | Completed | — | Spasticity | 100 | Sep 2012actual | — | 2020-11-05 |
| Lanreotide Autogel in the Symptomatic Treatment of Refractory DiarrheaNCT00891371results2015-09-29Percentage of Patients Having Minimum Reduction of 50% or Normalization (≤3 Stools/24hours) in the Mean Number of Stools (Mean of Last 7 Days)Open-label · Treatment | Phase 2/3 | Completed | Drug: lanreotide (Autogel formulation) | Diarrhea | 42 | Aug 2012actual | — | 2019-01-15 |
| Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following SurgeryNCT00500227observational | — | Completed | — | Acromegaly | 55 | Jul 2012actual | — | 2019-01-14 |
| Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive FunctionsNCT00814346results2016-03-28Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: EGb761®, Placebo | Alzheimer's Disease, Cognitive Impairment | 49 | Jul 2012actual | — | 2019-02-08 |
| Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical DystoniaNCT01261611results2019-09-24Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score Following First Treatment CycleRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A, Botulinum toxin type A · Drug: Placebo | Cervical Dystonia | 382 | May 2012actual | — | 2022-09-28 |
| Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaNCT00690898results2013-12-23Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)Open-label · Treatment | Phase 3 | Completed | Drug: Lanreotide autogel 120 mg | Acromegaly | 108 | Feb 2012actual | — | 2022-10-14 |
| Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mgNCT01257425results2014-05-26Area Under the Curve of Testosterone Serum Concentration Between D1 and D85 (AUC1-85d).Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Triptorelin Pamoate (Pamorelin® LA 11.25 mg) | Prostate Cancer | 109 | Feb 2012actual | — | 2019-02-08 |
| The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial CancerNCT00910091results2015-09-30Percentage of Women With Advanced or Recurrent Endometrial Cancer Who Have Neither Progressed Nor DiedRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: BN83495, Megestrol Acetate (MA) | Endometrial Cancer | 73 | Jan 2012actual | — | 2019-01-30 |
| Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and TreatmentNCT00489255results2013-05-20Incidence of Nausea and/or Vomiting During the Initial Titration of Apokyn® at the Visit on Day 1Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Tigan®, Placebo | Parkinson's Disease | 117 | Dec 2011actual | — | 2019-01-30 |
| Long-Term Treatment With rhIGF-1 in GHISNCT00571727results2023-07-06Annualized Height Velocity Up to 12 YearsOpen-label · Treatment | Phase 2/3 | Completed | Drug: mecasermin | Growth Hormone Insensitivity Syndrome | 92 | 2011-12-15actual | — | 2023-07-06 |
| Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate CancerNCT01020448results2015-07-15PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNAOpen-label · Diagnostic | Phase 3 | Completed | Drug: Triptorelin (Decapeptyl®) | Prostate Cancer | 339 | Nov 2011actual | — | 2019-01-30 |
| Efficacy of EGb761 in Patients Suffering From Friedreich AtaxiaNCT00824512results2013-05-21Creatine Rephosphorylation Rate Post ExerciseRandomized · Quadruple-masked · Supportive care | Phase 2 | Completed | Drug: EGb 761 120 mg, Placebo | Friedreich Ataxia | 22 | Oct 2011actual | — | 2020-04-07 |
| Safety and Efficacy Study of Dysport RU and Glabellar LinesNCT01333397results2015-10-30Percentage of Subjects as Responders in the ILA (Using Validated 4-point Photographic Scale) and the SSA of Glabellar Lines at Maximum FrownRandomized · Triple-masked · Treatment | Phase 2 | Completed | Biological: Botulinum toxin type A, Botulinum toxin type A · Drug: Placebo | Glabellar Frown Lines | 176 | Sep 2011actual | — | 2022-09-27 |
| Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapyNCT01251354results2015-09-02Determination of Clinical Benefit (CB), Defined as Sum of Patients Who Present Complete Response (CR), Partial Response (PR) or Stable Disease (SD) ≥12 Weeks (CB=CR+PR+SD≥12 Weeks) Using Response Evaluation Criteria in Solid Tumors (RECIST Version1.1)Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the primary endpoint will not be reached. | Drug: BN83495 | Endometrial Cancer | 6 | Jun 2011actual | — | 2019-01-14 |
| To Document the Effectiveness of BoNT-A Injection in Adult Subjects With Upper Limb Spasticity Following StrokeNCT01020500observationalResponder rate as defined by the achievement of the primary goal from the Goal Attainment Scale (GAS) following one BoNT-A injection cycle in accordance with routine practices | — | Completed | — | Muscle Spasticity | 469 | May 2011actual | — | 2020-11-06 |
| Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast CancerNCT01230970Intratumoural levels of sex hormonesNon-randomized · Open-label · Basic science | Phase 2 | Terminatedsponsor's stated reason: The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the primary endpoint will not be reached. | Drug: BN83495 | Breast Cancer | 2 | May 2011actual | — | 2019-01-07 |
| Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With AcromegalyNCT00994214results2016-02-10Percentage of Subjects With Mean GH ≤2.5 ng/mL and Normalised IGF-1Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Preliminary data from this study does not support expected inhibition of GH and IGF-1 | Drug: BIM 23A760 | Acromegaly | 109 | Feb 2011actual | — | 2019-11-22 |
| Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid SyndromeNCT01018953results2015-09-07Percentage of Patients With a Positive Overall Satisfactory Relief of Symptoms (Diarrhoea and/or Flushes) on the Likert ScaleOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Preliminary data from study NCT00994214 do not support expected inhibition of GH and IGF-1 | Drug: BIM 23A760 | Carcinoid Syndrome | 8 | Dec 2010actual | — | 2020-11-20 |
| Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious PubertyNCT00564850results2011-12-01Number of Participants With a GnRH-stimulated LH Level ≤3 IU/LOpen-label · Treatment | Phase 3 | Completed | Drug: Triptorelin pamoate 11.25mg (Decapeptyl® SR) | Precocious Puberty | 37 | Oct 2010actual | — | 2022-10-12 |
| BN83495 in Prostate CancerNCT00790374Absolute and percentage change in levels of hormones from baseline to D28/29 at 6 timepointsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BN83495 (Cohort 1), BN83495 (Cohort 2), BN83495 (Cohort 3) | Prostate Cancer | 17 | Oct 2010actual | — | 2019-01-15 |
| BN83495 Phase I in Post-menopausal WomenNCT01840488Change in percentage of steroid sulphatase (STS) inhibition in circulating Peripheral Blood Mononuclear Cells (PBMCs) after repeated daily therapyOpen-label · Treatment | Phase 1 | Completed | Drug: Irosustat (BN83495) | Breast Cancer | 50 | Sep 2010actual | — | 2019-11-22 |
| Somatuline Autogel Preference and Health Economy StudyNCT00681187results2012-03-13Subject Preference for Self or Partner AdministrationRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: lanreotide (Autogel formulation) | Neuroendocrine Tumour With Carcinoid Symptoms | 26 | Aug 2010actual | — | 2019-11-22 |
| rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 DeficiencyNCT00572156results2015-12-15Height VelocityRandomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: The study was prematurely terminated due to strategic reasons. | Drug: NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]) | Insulin-like Growth Factor-1 Deficiency | 106 | Apr 2010actual | — | 2023-03-30 |
| Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 DeficiencyNCT00330668results2011-06-27Height Velocity During BID Dosing PeriodOpen-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day | Drug: rh IGF-1 (mecasermin) | Growth Disorders | 114 | Feb 2010actual | — | 2020-08-14 |
| Factors Influencing Response to One BoNT-A Injection Cycle in Subjects Suffering From Idiopathic Cervical DystoniaNCT00833196observationalResponder rate at peak effect following one BoNT-A injection cycle without any deviations from routine practice | — | Completed | — | Idiopathic Cervical Dystonia | 404 | Feb 2010actual | — | 2019-08-16 |
| Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)NCT00710307observationalProportion of patients with a mean of the two basal IGF-1 measurements ≤-2.0 SDS, > -2.0 SDS and below 0 SDS, ≥ 0.0 SDS | — | Completed | Procedure: Blood sampling · Genetic: Genetic analysis | Idiopathic Short Stature | 275 | Jan 2010actual | — | 2019-01-15 |
| A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory ComplaintsNCT00276510EGb 761® efficacy on conversion rate of memory complaint to dementia of Alzheimer type by a survival analysisRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: EGb 761® (Tanakan®) · Other: Placebo | Memory Disorders, Age-Related, Retention Disorders, Cognitive | 2,878 | Nov 2009actual | — | 2019-01-15 |
| Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine TumoursNCT00326469Time to disease progression (appearance of 1+ new lesions or increase >or= to 20% of sum of the longest diameters of target lesions compared to the lower sum of maximum diameters recorded since the start of the study).Open-label · Treatment | Phase 2 | Completed | Drug: lanreotide (Autogel formulation) | Neuroendocrine Tumours | 30 | Nov 2009actual | — | 2020-11-05 |
| Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive BladderNCT00578097Number of episodes of urgency and frequency of micturition.Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: The study was terminated early due to poor recruitment. | Biological: Botulinum toxin type A · Drug: Placebo | Overactive Bladder | 81 | Jun 2009actual | — | 2019-11-22 |
| A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic StrokeNCT00276380results2018-02-19Percentage of Subjects With Modified Rankin Score of Less Than 3 at the End of Study Period.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: EGb761, Placebo, Acetylsalicylic acid | Stroke, Acute, Neurological Impairment | 204 | Mar 2009actual | — | 2019-01-08 |
| Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 DeficiencyNCT00125190results2010-04-15Height Velocity From Pretreatment (Week 0) to Week 34Open-label · Treatment | Phase 2/3 | Completed | Drug: rhIGF-1 (mecasermin) for a period of 86 weeks | Insulin-Like Growth Factor-1 Deficiency, Growth Disorders | 45 | Jan 2009actual | — | 2020-07-27 |
| Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar FasciitisNCT00447876results2017-06-23Responders Rate at Week 6 (Pain While Moving)Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Chronic Plantar Fasciitis | 40 | Jan 2009actual | — | 2019-11-22 |
| Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline AutogelNCT00447499results2010-12-20The Percentage of Subjects or Their Partners That Are Competent to Self-administer Somatuline Autogel at the End of the Study, (Week 24/Early Termination), as Assessed by the Competence Questionnaire Score.Open-label · Treatment | Phase 3 | Completed | Drug: Somatuline Autogel (lanreotide acetate) · Behavioral: Home administration | Acromegaly | 59 | Dec 2008actual | — | 2020-11-20 |
| Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)NCT00517491GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg.Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Administrative reasons | Drug: lanreotide (Autogel formulation) | Acromegaly | 0 | Dec 2008 | — | 2019-08-05 |
| Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal CarcinomatosisNCT00216372Percentage of responder patients (patient with 1 or less vomiting episode per day during at least 3 consecutive days or in whom nasogastric tube (NGT) has been removed during at least three consecutive days without vomiting recurrence)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Lanreotide (microparticle formulation) · Other: Placebo | Intestinal Obstruction, Carcinoma, Peritoneal Neoplasms | 80 | Oct 2008actual | — | 2020-11-05 |
| Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsNCT00383708results2018-07-23Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration PeriodOpen-label · Treatment | Phase 3 | Completed | Drug: lanreotide (Autogel formulation), Pegvisomant | Acromegaly | 125 | Oct 2008actual | — | 2022-09-27 |
| Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) DeficiencyNCT00125164results2010-04-30Height Velocity During the First Year - Intent to Treat (ITT)PopulationRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: rhIGF-1 (mecasermin, Tercica, Inc.) | Growth Disorders, Insulin-Like Growth Factor-1 Deficiency | 137 | Jul 2008actual | — | 2019-09-18 |
| Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAqNCT00234533results2018-08-09Insulin-Like Growth Factor I (IGF-I) Levels Measured Using the Timed Capillary Blood Spot SamplesOpen-label · Treatment | Phase 3 | Completed | Drug: Somatropin (rDNA origin) | Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism | 251 | Jul 2008actual | — | 2019-12-09 |
| To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.NCT00255372Bowel movement frequencyRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: PEG 4000 (Forlax®), Lactulose active and Lactulose placebo | Chronic Constipation | 88 | 2008-05-20actual | — | 2020-04-24 |
| Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's DiseaseNCT00500500Effect of EGb 761® on the ratio of the isoform of the protein precursor of beta amyloid platelets.Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Inability to recruit sufficient number of patients | Drug: EGb 761® (Tanakan®) | Alzheimer Disease | 40 | Apr 2008actual | — | 2023-06-26 |
| Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?NCT00455637To compare the effectiveness of 3 doses of Dysport (5, 10 or 15 Units/Kg/hip) in the management of chronic bilateral hip pain due to cerebral palsy in children/young people.Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Low levels of recruitment | Biological: Botulinum toxin type A | Cerebral Palsy | 6 | 2008-03-17actual | — | 2019-08-02 |
| Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)NCT00444639Percentage of patients achieving a plasma testosterone level ≤ 50 ng/dl (1,7 nmol/l).Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Low recruitment | Drug: Triptorelin (Decapeptyl®) | Prostate Cancer | 25 | Feb 2008actual | — | 2019-11-22 |
| Study to Assess the Efficacy and Safety of Dysport® in Cervical DystoniaNCT00447772results2018-07-30Change From Baseline in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) at the First On-treatment Visit (Week 4 or Week 12)Open-label · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A | Cervical Dystonia | 516 | Feb 2008actual | — | 2023-03-30 |
| Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical DystoniaNCT00288509results2010-04-02Change in Toronto Western Spasmodic Torticollis Rating Scale Total Score From BaselineOpen-label · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A | Cervical Dystonia | 108 | Jan 2008actual | — | 2022-09-28 |
| Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With AcromegalyNCT00444873Mean Insulin like Growth Factor 1 (IGF-1) and Growth Hormone (GH) levels at the beginning and end of the study and as proportion of patients conforming to internationally accepted levels.Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval | Acromegaly | 38 | Jan 2008actual | — | 2019-11-22 |
| BN80927 in Patients With Advanced Malignant Solid TumorsNCT01435096Maximum tolerated dose determined by incidence of dose limiting toxicity.Open-label · Treatment | Phase 1 | Completed | Drug: BN80927 | Malignant Solid Tumour | 56 | Oct 2007actual | — | 2020-03-03 |
| A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome.NCT00246142Changes in mean pain measured by Visual Analogue Scale (VAS) will be assessed.Randomized · Double-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A | Myofascial Pain Syndromes | 76 | 2007-06-27actual | — | 2019-07-29 |
| Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy TreatmentNCT00288522Extraocular muscle infiltration and edema exam by evaluating (at Day 0 and Weeks 4, 8 and 12): extraocular muscle size, proptosis and intraocular pressure (tonometry)Randomized · Double-masked · Treatment | Phase 2 | Terminated | Drug: Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days | Thyroid-Associated Ophthalmopathy | 5 | Apr 2007actual | — | 2020-06-02 |
| Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and ChildrenNCT00352989Cumulative faecal output (g/kg of body weight)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Smecta (Diosmectite), duration of treatment - 7 days | Diarrhoea | 302 | 2007-03-24actual | — | 2019-11-22 |
| Effectiveness of Smecta in the Treatment of Acute Diarrhoea in ChildrenNCT00352716Cumulative faecal output (g/kg of body weight)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Smecta (Diosmectite), duration of treatment - 7 days | Diarrhoea | 300 | 2007-02-01actual | — | 2019-11-22 |
| Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical DystoniaNCT00257660results2010-05-10Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)Randomized · Double-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Cervical Dystonia | 116 | Sep 2006actual | — | 2022-09-28 |
| Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the ArmNCT00216411Change in quality of life measured using the Assessment of Quality of Life questionnaire (12 question version).Randomized · Double-masked · Treatment | Phase 4 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Cerebrovascular Accident, Muscle Spasticity | 96 | 2006-07-20actual | — | 2019-07-29 |
| Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LARNCT00216398The percentage of patients with GH control (<5.0 mU.L) and normalised IGF-1 at week 44 compared to the baseline (Week 0) visit.Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Lanreotide (Autogel formulation) | Acromegaly | 8 | 2006-06-22actual | — | 2019-08-16 |
| Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain SyndromeNCT00134810Change in pain score for 'overall pain of the day during activity' between baseline and Week 6Randomized · Double-masked · Treatment | Phase 2 | Completed | Biological: Botulinum toxin type A | Myofascial Pain Syndromes | 381 | 2006-05-18actual | — | 2019-11-22 |
| Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain SyndromeNCT00149240The following parameters are measured at Inclusion, Week 2, Week 4, Week 8 and Week 12 of the study:Randomized · Double-masked · Treatment | Phase 2 | Completed | Biological: Botulinum toxin type A | Myofascial Pain Syndromes | 24 | 2006-02-02actual | — | 2019-11-22 |
| Somatuline Autogel: Acromegaly Self/Partner Injection StudyNCT00149188To assess the ability of patients or their partners to perform unsupervised Somatuline Autogel injections.Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Lanreotide (Autogel formulation) | Acromegaly | 30 | 2005-08-24actual | — | 2019-08-05 |
| Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back PainNCT00246155Pain reduction as assessed by the mean Visual Analogue Scale (VAS) during last 2 weeks. Assessments will be made at the initial time before injection and 1, 2, 3 months after injection.Non-randomized · Open-label · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A | Low Back Pain | 35 | 2005-07-01actual | — | 2019-07-26 |
| Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive FistulaeNCT00729313Number of patients with a reduction of fistula drainage volume > 50% of baseline at 72 hours.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Lanreotide microparticles, Placebo | Digestive Fistulae | 111 | Apr 2005actual | — | 2019-03-04 |
| Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)NCT00247559Change in severity of crow's feet at maximum smile at week 4, compared to baseline, assessed photographically by independent panelRandomized · Double-masked · Treatment | Phase 2 | Completed | Biological: Botulinum toxin type A | Lateral Canthal Lines | 221 | 2005-04-08actual | — | 2019-11-22 |
| Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)NCT00080015Overall objective response rate (tumour assessments should be performed every 6 weeks)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Diflomotecan (BN80915) | Small Cell Lung Cancer | 9 | Feb 2005actual | — | 2020-04-29 |
| A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or OctreotideNCT00234520observationalAssessment of the risk of new or worsening valvular regurgitation in any valve by echocardiography at baseline & 12 months | — | Completed | — | Acromegaly | 225 | 2005-02-18actual | — | 2019-08-02 |
| Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential BlepharospasmNCT00234507The functional disability as measured by the percentage of normal activity (PNA) derived from the Blepharospasm Disability Scale (BDS) at 4 weeks post-treatment.Randomized · Double-masked · Treatment | Phase 2 | Completed | Biological: Botulinum toxin type A | Blepharospasm | 120 | 2004-05-25actual | — | 2019-07-29 |
| Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With AcromegalyNCT00234572Mean serum GH levels determined from serial measurements at screening, weeks 4, 13, 14, 15, 16, 32 & 52, and in the event of early withdrawalRandomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: Lanreotide (Autogel formulation) | Acromegaly | 108 | 2003-01-03actual | — | 2019-08-02 |
| Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic PatientsNCT00210457Percentage of patients having a normal (age-adjusted) serum insulin-like growth factor 1 (IGF-1) level at end point (Week 48)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Lanreotide (Autogel formulation) | Acromegaly | 63 | 2002-07-15actual | — | 2020-03-31 |
| Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid SyndromeNCT00092287Target symptom frequency (flushing or stool frequency).Randomized · Open-label · Treatment | Phase 3 | Terminated | Drug: lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue) | Malignant Carcinoid Syndrome | 4 | — | — | 2020-04-30 |
| Post Marketing Surveillance Study of DysportNCT00210431observational- assessment of efficacy as assessed by treating physician at scheduled follow up visit | — | Completed | — | Blepharospasm, Hemifacial Spasm, Cervical Dystonia, Spasmodic Torticollis, Cerebral Palsy, Muscle Spasticity, Cerebrovascular Accident, Equinus Deformity, Facial Hyperdynamic Lines | 783 | — | — | 2020-03-31 |
| Efficacy Study of Dysport® in the Treatment of Anal Fissure.NCT00210444Healing of the anal fissure by complete re-epithelisation of the anal canal mucosa.Randomized · Open-label · Treatment | Phase 2 | Completed | Biological: Botulinum toxin type A | Anal Fissure | 168 | — | — | 2020-04-29 |
| Asian Botulinum Clinical Trial Designed for Early Stroke SpasticityNCT00234546Reduction of spasticity assessed by changes of the Modified Ashworth Spasticity Score from baseline of elbow and wrist flexors in supine anatomical positionRandomized · Double-masked · Treatment | Phase 4 | Completed | Biological: Botulinum toxin type A · Drug: Placebo | Muscle Spasticity, Cerebrovascular Accident | 162 | — | — | 2019-07-26 |
| Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial SpasmNCT00276315Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels)Randomized · Single-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin type A | Hemifacial Spasm | 332 | — | — | 2020-04-28 |
| Study to Evaluate Smecta® vs Placebo on the Time to Recovery Following an Acute Diarrhoea Episode in AdultsNCT00276328Time to recovery ie time (hours) from the first sachet intake to the first formed stool (this formed stool must have been followed by a non-watery stool)Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Diosmectite (Smecta®) | Diarrhea | 346 | — | — | 2020-04-28 |
| Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple SclerosisNCT00276341Evolution of Paced Auditory Serial Addition Test 3 and 2 seconds between baseline and week 24Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: EGb 761® (Tanakan®) | Multiple Sclerosis, Relapsing-Remitting | 47 | — | — | 2024-03-07 |
| Study of Long-term Use of Forlax® in Elderly Patients With Chronic ConstipationNCT00276354Clinical and biological tolerance with special attention to digestive and nutritional status. Clinical tolerance will be assessed by digestive symptomatology collected on a daily basisRandomized · Single-masked · Treatment | Phase 4 | Completed | Drug: PEG 4000 (Forlax ®) | Constipation | 246 | — | — | 2019-07-26 |
| Efficacy and Safety Study of Dysport® Used for Migraine ProphylaxisNCT00301665Significant decrease of the number of migraine attacks with Dysport® compared to placebo.Randomized · Double-masked · Prevention | Phase 2 | Completed | Biological: Botulinum toxin type A | Migraine | 138 | — | — | 2020-04-24 |
| Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate CancerNCT00415246Proportion of patients with testosterone serum levels maintained below the castration threshold of 50 ng/dL.Non-randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: The preliminary data do not support the expected sustainable blood levels of triptorelin for a duration of 4 months in all patients. | Drug: Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study) | Prostate Cancer | 100 | — | — | 2019-11-22 |
| A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone DeficiencyNCT00455884observationalIncidence of serious adverse events | — | Completed | — | Growth Hormone Disorders | 546 | — | — | 2019-01-14 |
| Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With AcromegalyNCT00499993Growth hormone assessmentNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: lanreotide (Autogel formulation), duration of treatment 46-48 weeks | Acromegaly | 63 | — | — | 2019-01-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19